Sequence: Multicomponent peptide (poly-L-lysine dendron + GALA + TAT) (no stearic acid)
| Experiment Id | EXP001187 |
|---|---|
| Paper | Design and evaluation of a stearylated multicomponent peptide-siRNA nanocomplex for efficient cellul |
| Peptide | DEN-K(GALA)-TAT |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | Peptide/siRNA molar ratios tested 25–125 (uptake); 50–200 for DLS; complexes in 20 mM HEPES pH 7.2, 30 min RT |
| Rna Concentration | 20 nM Alexa488-siRNA (uptake assays); 100 ng siRNA for gel shift |
| Mixing Ratio | Peptide:siRNA molar ratio |
| Formulation Format | Electrostatic peptide/siRNA complex |
| Formulation Components | DEN-K(GALA)-TAT + eGFP siRNA in 20 mM HEPES buffer pH 7.2 (30 min incubation) |
| Size Nm | 101.00 |
| Zeta Mv | 44.40 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa cells (uptake) / stable eGFP-HeLa (knockdown comparisons) |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake / internalization (confocal microscopy and flow cytometry); functional knockdown not observed |
| Output Value | Lower uptake than lipidic analog; no eGFP knockdown reported for this analog under tested conditions |
| Output Units | |
| Output Notes | Non-lipidic analog showed reduced siRNA-associated fluorescence vs stearylated system; authors state analogs lacking STR or GALA could not mediate eGFP knockdown (data not shown). |
| Toxicity Notes | Low cytotoxicity under assay conditions (∼7% viability loss at 2 µM vector with 20 nM siRNA). |
| Curation Notes |